8-K: Envoy Medical Reports First Quarter 2025 Results, Highlights Progress on Acclaim Cochlear Implant Trial

Envoy Medical announces its Q1 2025 financial results and provides an update on its pivotal clinical study for the fully implanted Acclaim cochlear implant, including securing additional funding and completing enrollment of the first stage of the trial.

Summary

• Envoy Medical reported its financial results for the first quarter ended March 31, 2025.
• The company secured an additional $10 million in funding to advance the Pivotal Clinical Trial.
• Enrollment of 10 participants in the first stage of the Pivotal Clinical Trial of the Acclaim cochlear implant has been completed.
• Six of the 10 participants have been activated, with the remaining four scheduled for activation in May.
• Two participants have completed 1-Month Follow-Up visits.
• No Serious Adverse Events or Unanticipated Adverse Device Effects have been reported.
• Net revenues decreased by $13 thousand compared to the same period in 2024 due to supply chain limitations affecting battery replacement sales.
• Cost of goods sold increased by $73 thousand due to increased headcount, new supplier expenses, and an inventory reserve adjustment.
• R&D expenses increased by $400 thousand due to increased headcount and contractor expenses related to the Acclaim CI pivotal clinical study.
• Sales and marketing expenses increased by $33 thousand due to increased headcount, travel, and a patient engagement program.
• General and administrative expenses decreased by $284 thousand due to reduced legal fees and professional service costs.
• Cash and cash equivalents were approximately $5.3 million as of March 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in the clinical trial and additional funding, but tempered by the revenue decrease and operating loss.

Positives

• The company secured an additional $10 million in funding.
• Enrollment of the first 10 participants in the Acclaim CI pivotal trial was completed.
• Activations and follow-up visits are within expectations.
• Modifications appear to address previously discussed electrical system noise.
• General and administrative expenses decreased by $284 thousand.

Negatives

• Net revenues decreased by $13 thousand due to supply chain limitations.
• Cost of goods sold increased by $73 thousand.
• R&D expenses increased by $400 thousand.
• The company reported an operating loss of $5.107 million.

Risks

• The Acclaim Cochlear Implant is an investigational device and is limited by Federal law to investigational use.
• The company faces risks related to the regulatory approval process for medical devices.
• Competition in the medical device industry could impact the company's success.
• Disruptions in relationships with suppliers or in the company's own production capabilities could affect operations.
• Changes in the need for capital and the availability of financing could impact the company's ability to fund its needs.

Future Outlook

The company is focused on advancing its pivotal clinical study for the Acclaim CI and believes a meaningful percentage of patients will be drawn to a fully implanted solution.

Management Comments

• Brent Lucas, CEO of Envoy Medical, stated that the company is pleased with the positive progress of the pivotal clinical study and the reported excitement from the investigational sites.
• He believes that a meaningful percentage of patients who are candidates for cochlear implants will be drawn to a fully implanted solution.
• He expressed excitement about Envoy Medical's future and its position in the hearing industry.

Industry Context

Envoy Medical is operating in the hearing health industry, focusing on fully implanted hearing devices. The Acclaim CI aims to address severe to profound sensorineural hearing loss, competing with traditional cochlear implants and hearing aids. The Esteem FI-AMEI is the only FDA-approved, fully implanted hearing device for adults diagnosed with moderate to severe sensorineural hearing loss.

Comparison to Industry Standards

• Envoy Medical's Acclaim CI is positioned as a first-of-its-kind fully implanted cochlear implant, differentiating it from traditional cochlear implants that require external components.
• Competitors in the cochlear implant market include companies like Cochlear Limited and MED-EL, which offer traditional cochlear implant systems.
• The Esteem FI-AMEI competes with hearing aids and other partially implanted hearing devices, offering a fully implanted solution with 24/7 hearing capability.
• The company's focus on fully implanted devices aligns with a trend towards more discreet and convenient hearing solutions.

Stakeholder Impact

• Shareholders may be impacted by the financial results and progress of the clinical trial.
• Employees are impacted by changes in headcount and the company's overall performance.
• Customers (patients) are impacted by the development and availability of new hearing solutions.
• Suppliers are impacted by the company's production needs and relationships.

Next Steps

• The company will continue to advance the Pivotal Clinical Trial for the Acclaim CI.
• The remaining four participants in the clinical trial are scheduled for activation in May.
• The company will continue to monitor and analyze data from the clinical trial.

Key Dates

Keywords

Acclaim Cochlear Implant, Cochlear Implant, Envoy Medical, Pivotal Clinical Trial, Financial Results, Hearing Health, Esteem FI-AMEI